Yongdoo Choi
Overview
Explore the profile of Yongdoo Choi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
1061
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moon Y, Hong C, Kim Y, Kim J, Ye S, Kang E, et al.
Int J Mol Sci
. 2025 Jan;
25(24.
PMID: 39769013
The cost-effectiveness of whole exome sequencing (WES) remains controversial due to variant call variability, necessitating sensitivity and specificity evaluation. WES was performed by three companies (AA, BB, and CC) using...
2.
Kim H, Yoon H, Lee Y, Lim K, Seong J, Park S, et al.
Biomater Sci
. 2024 Nov;
12(24):6382-6391.
PMID: 39498637
Accurate tumor localization is crucial for the success of minimally invasive surgery, as it minimizes the resection of normal tissues surrounding tumors. Traditional methods for marking gastrointestinal (GI) tumors, such...
3.
Li Y, Lee H, Go E, Lee S, Han C, Choi Y
J Control Release
. 2024 Oct;
376:108-122.
PMID: 39384151
Immune checkpoint inhibitors (ICIs) are innovative immunotherapeutic agents for cancer. However, their low therapeutic efficacy in patients with large or rapidly growing tumors, along with their high cost, represents a...
4.
Kim H, Liu M, Park C, Lee B, Jang H, Choi Y
J Mater Chem B
. 2024 Aug;
12(42):10877-10885.
PMID: 39206756
In clinical practice, determining programmed death-ligand 1 (PD-L1) expression is crucial for selecting patients and monitoring immune checkpoint blockade therapies. Currently, PD-L1 expression is quantified using immunohistochemistry (IHC). However, IHC-based...
5.
Kim H, Liu M, Choi Y
Pharmaceutics
. 2024 Aug;
16(8).
PMID: 39204379
The efficacy of glioblastoma treatment is closely associated with complete tumor resection. However, conventional surgical techniques often result in incomplete removal, leading to poor prognosis. A major challenge is the...
6.
Li Y, Sung Y, Choi Y, Choi Y, Goh S
Int J Mol Sci
. 2024 Jul;
25(13).
PMID: 39000513
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, including abemaciclib, have been approved for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced, and metastatic breast cancer....
7.
Choi Y, Lee H, Song J, Baek M, Mun S
Food Sci Biotechnol
. 2024 Jan;
33(2):431-439.
PMID: 38222904
The objective of this study was to improve water solubility of the rice protein (RP) by forming complexes with anionic polysaccharides, such as sodium alginate (SA) and xanthan gum (XG)....
8.
Shin Y, Park Y, Lee H, Choi Y, Eom J
Pharmaceutics
. 2023 Mar;
15(3).
PMID: 36986791
We report real-time monitoring of colorectal cancer, lymph node metastasis of colorectal cancer cells, and tumor growth inhibition through photodynamic therapy (PDT) using a near-infrared fluorescence diagnostic-therapy system with a...
9.
Shih C, Choi Y, Yeh C, Chen P
Front Chem
. 2022 Dec;
10:1079927.
PMID: 36479440
No abstract available.
10.
Madhi H, Lee J, Choi Y, Li Y, Kim M, Choi Y, et al.
Adv Sci (Weinh)
. 2022 Aug;
9(29):e2202702.
PMID: 35975458
Programmed death-ligand 1 (PD-L1) is a major target to cancer immunotherapy, and anti-PD-L1 and anti-PD-1 antibody-mediated immunotherapy are being increasingly used. However, immune checkpoint inhibitors (ICIs) are ineffective in treating...